Our technology
Good safety & pharmacokinetic profile
Our molecules are well tolerated* in in vivo settings both in acute and chronic conditions with good pharmacokinetic parameters, oral bioavailability, and cardiac safety.
Test passed:
- genotoxicity: in vitro micronucleus test in human lymphocytes
- mutagenicity: Ames Test in Salmonella Typhimurium and Escherichia coli
- oral bioavailability: comparative pharmacokinetic analysis in vivo versus gavage administration
- cardiac safety: hERG channel test
* according to the OECD guidelines and Good-Laboratory Practice (GLP) criteria
IP protection
ChemiCare holds exclusive patent life-long exploitation license rights on the following two patents filed by the University of Piemonte Orientale:
WO/2017/212414
WO/2021/165735
Easy manufacturing
Our molecules have been synthesized through the click chemistry approach, which allows:
- parallel preparation of a large number of molecules;
- straightforward exploration of the chemical space during the early drug discovery phase;
- easy chemical refinement of hit compounds during the hit-to-lead process in order to meet the pharmacokinetic and pharmacodynamic requirements.
Our pipeline
[Update January 2024]